阿托伐他汀对短暂性脑缺血患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A_2的影响

The Effectiveness of Atorvastatin on Hs-CRP and Lp-PLA_2 in the Serum of Patients with Transient Ischemic Attack

目的探讨阿托伐他汀对短暂脑缺血患者血浆超敏C反应蛋白和脂蛋白相关磷脂酶A2的影响。方法 68例短暂脑缺血患者随机分为两组,对照组33例,治疗组35例;对照组采用常规治疗,治疗组在常规治疗的基础上加用阿托伐他汀20 mg,1次/天,口服,两组共治疗30 d。治疗前后测定患者血浆超敏C反应蛋白(hs-CRP)和脂蛋白相关磷脂酶A2(Lp-PLA2)的浓度。结果两组治疗后均明显降低血浆hs-CRP和LP-PLA2的表达,并且治疗组降低二者更明显(P<0.05)。两组均未出现严重的不良反应。结论阿托伐他汀可以明显降低短暂脑缺血患者血浆hs-CRP和Lp-PIA2的表达。

Objective To study the effectiveness of atorvastatin on high sensitivity c-reactive protein （hs-CRP） and lipoprotein-associated phospholipaseA2（Lp-PLA2） in the serum of patients with transient ischemic attack. Methods Sixty-Eight patients with Transient ischemic attack were randomly divided into two groups. The control group（n=33 cases） and the treatment group（n=35 cases）.The paitents in the control group were treated through the conventional. Treatment and the patients in the treatment group were treated thorough atorvastatin plus the conventional treatment. Atorvastatin was used through orally 20mg once daily. The hs-CRP and Lp-PLA2 were detected before and after treatment. Results The hs-CRP and Lp-PLA2 in serum of patients were decreased after treatment. The re was a significant difference between two groups（P＆lt;0.05）. There were not any serious adverse events in the both groups. Conclusion Atorvastatin can significantly decrease hs-CRP and Lp-PLA2 in the serum of patients with transient ischemic attack.